Rapid progress in identifying biomarkers that are hallmarks of disease has increased
demand for high-performance detection technologies. Implementation of electrochemical …

The increasing number of deaths from cardiovascular diseases has become a substantial
concern in both developed and underdeveloped countries. Rapid and on-site monitoring of …

This manuscript describes the production of molecularly imprinted polymer nanoparticles
(nanoMIPs) for the cardiac biomarkers heart-fatty acid binding protein (H-FABP) and ST2 by …

Fatty acid-binding proteins, whose clinical applications have been studied, are a family of
proteins that reflect tissue injury. Heart-type fatty acid-binding protein (H-FABP) is a marker …

The assessment of chest pain patients presenting to the emergency area (EA) is still a
clinical challenge, as the majority of patients are not diagnosed with acute coronary …

Since cardiovascular diseases (CVDs) are globally one of the leading causes of death, of
which myocardial infarction (MI) can cause irreversible damage and decrease survivors' …

Cardiac biomarkers have become pivotal to the clinical practice of cardiology, but there
remains much to discover that could benefit cardiology patients. We review the discovery of …

Background Point-of-care tests (POCT) can assist general practitioners (GPs) in diagnosing
and treating patients with acute cardiopulmonary symptoms, but it is currently unknown if …

Background Although cardiac troponin is the cornerstone in diagnosis of acute myocardial
infarction (AMI), the accuracy is still suboptimal in the early hours after chest pain onset. Due …

Background: Heart-type fatty acid-binding protein (H-FABP) is a novel biomarker for
myocardial injury. We compared the use of H-FABP with serum levels of cardiac troponin-T …